Trump’s tariff threats and Kennedy’s anti-vaccine stance makes US a hostile environment for pharma companies ...

GSK completes acquisition of Boston-based, clinical-stage biopharma company, IDRx, Inc.

GSK plc has completed its previously announced acquisition of IDRx Inc., a Boston-based, clinical-stage biopharmaceutical ...

GSK (GSK) plc announced that it has completed the acquisition of IDRx, Inc., a Boston-based, clinical-stage biopharmaceutical company dedicated ...

GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, ...

In corporate news, Prosus has agreed to acquire Just Eat Takeaway.com for around EUR4.1 billion. Here is what you need to know at the London market open: FTSE 100: called down 3.1 points at 8,656.27 ...

GSK on Monday also said it has start the GBP2 billion buyback programme that it announced earlier this month, starting with an initial GBP700 million tranche.

Blueprint Medicines Corporation BPMC reported fourth-quarter 2024 adjusted loss of 79 cents per share, wider than the Zacks ...

Blueprint Medicines (BPMC) sees strong AYVAKIT growth, 2025 revenue guidance at $680M-$710M. Discover insights on their market expansion & $2B 2030 vision.

Achieved $479.0 million in AYVAKIT® (avapritinib) global net product revenues in 2024, including $144.1 million in the fourth quarter -- -- Anticipate global AYVAKIT ...

January is in the books, and markets are still waiting on a big rebound in the dealmaking space. Investors rooting for increased M&A and a flurry of IPOs will have to be patient as Q1 tracks with ...

The company is hoping its bet on cancer drugs will pay off, agreeing in January to buy cancer biotech IDRx for as much as US$1.15 billion. The return to oncology is part of a strategic shift as it ...